BIOMAT Database Logo BIOMAT Database Logo

Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission. 1988

G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
Service d'Hématologie Pédiatrique, CHU Timone, Marseille, France.

Eleven children between the ages of 1 and 16 years with acute non-lymphoblastic leukemia (ANLL) in first remission were included in a study of double unpurged autologous bone marrow transplantation (ABMT). Prior to each ABMT patients received massive chemotherapy with melphalan at a dosage of 140 mg/m2. The first ABMT was done within a median of 4 months after the achievement of complete remission. As soon as the children had adequate hematologic recovery, a second marrow collection was done, followed by a second course of melphalan and a second ABMT. The duration of aplasia was significantly longer after the second ABMT than after the first, but the non-hematologic toxicity was relatively mild in each case and no patient died from the procedure. Four patients relapsed and seven are alive in unmaintained complete remission with a median duration of leukemia-free survival of 29 months (range 15-56 months) after the first ABMT. These data demonstrate the feasibility of repeating ABMT after melphalan in children with ANLL. The eventual impact of such therapy needs to be demonstrated in prospective randomized studies.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
Autologous Unpurged Bone Marrow Transplantation for Acute Non Lymphoblastic Leukemia in First Remission.
January 1991, Leukemia & lymphoma,
G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
Autologous unpurged bone marrow transplantation for acute non-lymphoblastic leukaemia in first complete remission.
November 1988, Bone marrow transplantation,
G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
Repeated high-dose-melphalan with autologous bone marrow transplantation in acute non lymphocytic leukemia.
November 1985, Revue francaise de transfusion et immuno-hematologie,
G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission.
August 1990, Cancer,
G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.
January 1990, Bone marrow transplantation,
G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission.
December 1993, Blood,
G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
High-dose chemotherapy with noncryopreserved autologous bone marrow transplantation for acute myeloid leukemia in first complete remission.
January 1990, Haematology and blood transfusion,
G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
Transplantation of unpurged autologous bone-marrow in acute myeloid leukaemia in first remission.
November 1984, Lancet (London, England),
G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
Allogenic versus autologous marrow transplantation for patients with acute non lymphoblastic leukemia in first complete remission.
January 1990, Haematologica,
G Michel, and D Maraninchi, and F Demeocq, and H Perrimond, and D Blaise, and M H Gaspard, and A M Stoppa, and J A Gastaut, and G Lepeu, and G Novakovitch
Autologous bone marrow transplantation (ABMT) using unpurged marrow as intensification for first complete remission in acute leukaemia (AL).
January 1989, Folia haematologica (Leipzig, Germany : 1928),
Copied contents to your clipboard!